Compare Cytokinetics Inc (CYTK) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Weibo Corp — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Weibo Corp trades at $7.87 (market cap $1.93B). The key difference: Cytokinetics Inc is far larger — about 5.5× Weibo Corp's market cap, and Weibo Corp pays a 7.75% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | WB | |
|---|---|---|
Market Cap | $10.63B | $1.93B |
Sector | Technology | Media |
52-Week High | $87.26 | $12.83 |
52-Week Low | $34.31 | $7.20 |
Enterprise Value | $10.74B | $1.20B |
Dividend Yield | — | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
Weibo (WB) trades at $7.76, down 2.82% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 5.5 and P/B of 0.5. The company maintains strong profitability with 21.15% net margins and $449M net income in 2025, but has missed earnings expectations for three consecutive quarters. Cash flow trends show volatility, with 2024 net cash flow negative $694M despite solid operational performance.
The stock presents a value opportunity given deep discount to balance sheet value, but faces competitive pressures and user engagement challenges. Analyst sentiment is mixed with 45% buy ratings, while technical indicators suggest near-term weakness. Key risks include Chinese regulatory environment and competition from Douyin/WeChat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
